A patient exposed to teriparatide developed osteosarcoma in a prior radiation field, with uncertain drug attribution.
In plain wordsA patient developed bone cancer after teriparatide and prior radiation. The drug's contribution was uncertain.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- Not applicableOsteosarcoma
- Study
n = 1
- Outcome group
- Adverse events · Cancer
- Studied dose
- Dose not stated
Source sentences
After the first case of suspected osteosarcoma was reported in December 2005, we encountered a second possible teriparatide-induced osteosarcoma less than a year later.
2 context sentences(design, population, supporting numbers)
Given the location of the sarcoma within the field of radiation and the limited exposure to teriparatide before diagnosis, it is unlikely that teriparatide played the predominant role in the emergence of this patient's osteosarcoma. We cannot, however, exclude the possibility that teriparatide magni…
As a participating institute of that surveillance program, we report upon the second person with potential teriparatide-induced osteosarcoma, in this case, complicated by a history of pelvic radiation.